drugset / Trial / NCT01990846

Safety, Tolerability, and PK of Escalating Doses of Flufirvitide-3 Dry Powder for Inhalation in Healthy Subjects

NCT01990846 ↗

Phase 1 Completed 68 enrolled Autoimmune Technologies, LLC
RandomizedParallel-groupTriple-blindTreatment

Summary

To evaluate the safety, tolerability and pharmacokinetics (PK) of single,and repeat escalating doses of FF-3 dry powder administered via inhalation in healthy adult subjects

Timeline

Start
2014-03
Primary completion
2015-02
Completion
2015-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Flufirvitide 3 Unknown — Inhaled

Indications